Allogeneic Hematopoietic Stem-Cell Transplantation Improves Disease-Free Survival Compared to Pediatric-Inspired Berlin-Frankfurt-M ünster Chemotherapy in Adult Acute Lymphoblastic Leukemia.

CONCLUSION: AHSCT currently offers no special OS advantage but increases DFS compared to the BFM-95 regimen. AHSCT may be considered at first complete remission in patients at low risk of transplant-related mortality. PMID: 33451957 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/33451957?dopt=Abstract

Source: Clinical Lymphoma and Myeloma - January 12, 2021 Category: Cancer & Oncology Authors: Aladag E, Aktimur SH, Aydın Ö, Demiroglu H, Buyukasik Y, Aksu S, Ozcebe OI, Haznedaroglu IC, Sayinalp N, Turgut M, Goker H Tags: Clin Lymphoma Myeloma Leuk Source Type: research